2025 年 03 月 11 日 公司点评 买入/维持 爱美客(300896) 目标价: 昨收盘:174.89 公司点评：拟收购韩国 Regen，国际化战略加速发展 ◼ 走势比较 (50%) (36%) (22%) (8%) 6% 20% 24/3/11 24/5/22 24/8/2 24/10/13 24/12/24 25/3/6 爱美客 沪深300 ◼ 股票数据 | 总股本/流通(亿股) | 3.03/2.09 | | --- | --- | | 总市值/流通(亿元) | 529.2/364.85 | | 12 个月内最高/最低价 | 358/132.81 | | (元) | | 相关研究报告 <<2024Q1 财报点评：业绩符合预期， 期待核心产品驱动增长>>--2024- 04-28 <<2023 年业绩点评：全年业绩符合预 期，期待多元管线接力成长>>-- 2024-03-20 <<爱美客 2023 年半年度业绩预告点 评：业绩增长超预期，终端复苏+新品 红利，看好全年持续兑现>>--2023- 08-04 证券分析师：郭彬 E-MAIL：guobin@tpyzq.com 分析师登记编号：S1190 ...

2025 年 03 月 11 日 公司点评 买入/维持 爱美客(300896) 目标价: 昨收盘:174.89 公司点评：拟收购韩国 Regen，国际化战略加速发展 ◼ 走势比较 (50%) (36%) (22%) (8%) 6% 20% 24/3/11 24/5/22 24/8/2 24/10/13 24/12/24 25/3/6 爱美客 沪深300 ◼ 股票数据 | 总股本/流通(亿股) | 3.03/2.09 | | --- | --- | | 总市值/流通(亿元) | 529.2/364.85 | | 12 个月内最高/最低价 | 358/132.81 | | (元) | | 相关研究报告 <<2024Q1 财报点评：业绩符合预期， 期待核心产品驱动增长>>--2024- 04-28 <<2023 年业绩点评：全年业绩符合预 期，期待多元管线接力成长>>-- 2024-03-20 <<爱美客 2023 年半年度业绩预告点 评：业绩增长超预期，终端复苏+新品 红利，看好全年持续兑现>>--2023- 08-04 证券分析师：郭彬 E-MAIL：guobin@tpyzq.com 分析师登记编号：S1190 ...

Core Viewpoint - The company, Aimeike, is making a significant move towards international expansion by acquiring 85% of REGEN Biotech, a leading South Korean medical aesthetics company, for $190 million, which is expected to enhance its market position and drive future growth [1][2][3]. Group 1 - Aimeike's stock surged approximately 15%, surpassing 200 yuan, with a trading volume of nearly 3.1 billion yuan following the announcement of the acquisition [1]. - The acquisition involves Aimeike's wholly-owned subsidiary, Imeik (HK) Limited, and Aisheng Shourui (HK) Limited, establishing Imeik International Limited to facilitate the purchase [1][2]. - REGEN Biotech specializes in the research, production, and sales of medical materials, medical devices, and pharmaceuticals, with notable products including AestheFill and PowerFill [2]. Group 2 - The transaction is a key step in Aimeike's international strategy, aimed at solidifying its leading position in the medical aesthetics injection filler market and driving sustainable growth [2][3]. - Post-acquisition, the integration of resources between Aimeike and REGEN Biotech is expected to create synergies, enhancing product access to international markets and increasing revenue from these markets [3]. - The acquisition will allow Aimeike to consolidate REGEN Biotech into its financial statements, expanding its asset base and improving future profitability and core competitiveness [3].